MoonLake Immunotherapeutics(MLTX)
ZUG, SwitzerlandBiotechnology
Focus: MoonLake Immunotherapeutics is a newly public (2024) Swiss biotech specializing in tri-specific nanobody therapeutics, with a focused pipeline in dermatology and rheumatology. The company operates at mid-cap scale (51-200 employees) with a single lead program in late-stage development.
Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
10-3 this month
Stable — net -3 jobs in 30d
3 added, 6 removed. Backfill posture.
Should You Work at MoonLake Immunotherapeutics?
AI assessmentBest suited for risk-tolerant candidates seeking early-stage upside in a novel modality; unsuitable for those prioritizing stability or career optionality.
Why Work Here
- Rare technology platform: tri-specific nanobody approach is differentiated from standard monoclonal antibodies, offering exposure to novel mechanism validation.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Sonelokimab
Relative BioequivalenceClinical Trials (1)
NCT06994936An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
Phase 1Help build intelligence for MoonLake Immunotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.